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Antigen-Specific CD4 Cells Assist CD8 T-Effector
Cells in Eliminating Keratinocytes
Jennifer K. Broom1, Andrew M. Lew2, Hiroaki Azukizawa3, Tony J. Kenna1, Graham R. Leggatt1 and
Ian H. Frazer1
Keratinocytes expressing tumor or viral antigens can be eliminated by antigen-primed CD8 cytotoxic T cells.
CD4 T-helper cells help induction of CD8 cytotoxic T cells from naive precursors and generation of CD8 T-cell
memory. In this study, we show, unexpectedly, that CD4 cells are also required to assist primed CD8 effector
T cells in rejection of skin expressing human growth hormone, a neo-self-antigen, in keratinocytes. The
requirement for CD4 cells can be substituted by CD40 costimulation. Rejection of skin expressing ovalbumin
(OVA), a non-self-antigen, by primed CD8 cytotoxic T cells can in contrast occur without help from antigen-
specific CD4 T cells. However, rejection of OVA expressing keratinocytes is helped by antigen-specific CD4
T cells if only low numbers of primed or naive OVA-specific CD8 T cells are available. Effective immunotherapy
directed at antigens expressed in squamous cancer may therefore be facilitated by induction of tumor antigen-
specific CD4 helper T cells, as well as cytotoxic CD8 T cells.
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INTRODUCTION
Development of epithelial malignancy is regulated by the
immune system, as chronic immunosuppression after organ
transplantation is associated with a greatly increased risk of
squamous cancer. Many cancers of epithelial origin express
tumor-specific modified self-proteins as neo-self-antigens
(Buckwalter and Srivastava, 2008). Epithelial cancer can also
arise from skin persistently infected with virus, including
human papillomavirus (Al-Daraji and Smith, 2009) and
Merkel tumor-associated retrovirus (Feng et al., 2008), and
these tumors continue to express virus-encoded antigen.
Evidently, neo-self- or viral antigens expressed in squamous
epithelial cancer fail to induce an immune response adequate
to eliminate cancer. A better understanding of the require-
ment for effective immune-mediated elimination of keratino-
cytes expressing viral or neo-self-antigen would therefore
assist in the design of appropriate immunotherapeutic
interventions for squamous epithelial cancer.
We have developed a murine model to study the
requirements for effective immunotherapy directed at antigen
expressed in keratinocytes. Skin expressing a non-self- or neo
antigen as a transgene in keratinocytes from a keratin
promoter is grafted to a syngeneic nontransgenic recipient
(Zhong et al., 2004). This allows us to study the requirements
for inducing and delivering an effective immune response to
antigen expressed only in keratinocytes, and not directly
presented to the immune system by professional antigen-
presenting cells (APC).
The fate of a graft of skin expressing non-self antigen in
keratinocytes depends on the antigen. Some antigens, includ-
ing papillomavirus nonstructural proteins, fail to invoke
spontaneous rejection of grafts (Dunn et al., 1997), allowing
the study of the requirements for effective induction of
immunity after antigen cross-presentation from keratinocytes.
Other antigens, including ovalbumin (OVA) (Holcmann et al.,
2009) and human growth hormone (hGH) (Zhong et al., 2004),
which is closely related in sequence to mouse growth
hormone and therefore a neo-self-antigen in the mouse,
induce spontaneous graft rejection, allowing the study of the
elimination of keratinocytes by primed T cells in a second graft
after immune-mediated elimination of a priming graft.
To prime a cytotoxic CD8 effector T-cell response from
naive antigen-specific CD8 T-cell precursors, antigens
expressed only in epithelial cells must be cross-presented
by professional APC, particularly by dermal dendritic cells in
the local lymph node (Bedoui et al., 2009). CD4 helper
T cells are required to enable priming of memory and effector
CD8 T cells (Schuurhuis et al., 2000; Janssen et al., 2003;
Smith et al., 2004). CD4 T cells also assist in the maintenance
of a pool of memory CD8 T cells (Sun et al., 2004). However,
once they are primed by antigen, CD8 effector T cells are
held capable of eliminating their cognate target cells without
the need for CD4 T-cell help. Recent in vitro evidence
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suggests, however, that CD4 T cells can assist in secondary
responses to cross-presented but not directly presented
antigen (Blachere et al., 2006). We have also previously
shown a requirement for CD4 cells in a secondary immune
response to hGH in FVB mice of H-2qH-2b genetic
background (Zhong et al., 2008). To extend this observation
to mice of a genetic background more commonly used for
studies of immune physiology and to therefore enable further
dissection of the mechanisms by which CD4 cells contribute
to elimination of keratinocytes after priming or immuniza-
tion, we created K14.hGH transgenic mice on a C57/Bl6
genetic background. We evaluated the role of CD4 T cells in
rejection of epithelial cells expressing various nonself-
antigens using these mice. Here, we present data showing
that CD4 T-cell help improves the efficacy of rejection by
already primed CD8 effector T cells of skin expressing either
non self-antigen or neo-self-antigen in keratinocytes, and
demonstrate that the requirement for CD4 cell responses can
be substituted by CD40 costimulation.
RESULTS
Second-set syngeneic skin grafts expressing hGH as a neo-
self-antigen are more rapidly rejected by C57Bl/6 recipients
than the primary graft
We grafted skin expressing antigen as a transgene in
keratinocytes in naive C57Bl/6 (C57) recipient animals, and
measured time-to-graft rejection to assess the immune response
induced to the expressed antigen. We first studied recall
responses to hGH, a near homolog of mouse growth hormone
representing modified self (neo-self). Animals that rejected an
hGH transgenic graft were considered primed to hGH, and
received a further hGH graft. Primary hGH grafts on C57 mice
were rejected in a median of 31.5 days (Figure 1a), as was
observed for C57 FVB mice and in contrast to the findings for
FVB mice, which rarely reject primary hGH grafts (Zhong et al.,
2004). Second hGH grafts placed on graft-primed C57
recipients were rejected with a median survival time of 21
days, significantly earlier than the initial graft (P¼ 0.018). The
recall response to hGH by C57 mice is consistent with
observations for FVBC57 mice (Zhong et al., 2004).
Rejection of second-set hGH skin grafts requires CD4 cells
Rejection by FVBC57 mice of skin expressing hGH antigen
in keratinocytes requires both CD4 and CD8 T cells (Zhong
et al., 2004, 2008). To establish for C57 mice whether CD4 T
cells are required for rejection of hGH transgenic skin following
priming, hGH graft-primed C57 animals were depleted of CD4
T cells, and given a second hGH graft (Figure 1b). Rejection of
second hGH grafts occurred in 8% (1 out of 13) of CD4-
depleted recipients, compared with 87% (7 out of 8) of CD4-
replete recipients (Po0.0001). Thus, CD4 T cells are important
not only for priming but also for optimal rejection by CD8
T cells of hGH grafts from an hGH graft-primed C57 animal.
CD40 stimulation abrogates the requirement for CD4 cells in
rejection of second-set K14hGH.H-2b skin grafts
CD4 T-helper cells provide costimulatory signals to dendritic
cells to assist in priming antigen-specific primary cytotoxic
T-cell responses (Schoenberger et al., 1998). Costimulatory
signals delivered by dendritic cells to activated T cells have
recently been shown to have a significant role in secondary
immune responses (Wang et al., 2007; Salek-Ardakani et al.,
2008). We therefore investigated whether CD40 stimulation
could replace the requirement for CD4 T cells and enable
effector T-cell function and hence graft rejection in an hGH-
primed animal. Mice that had rejected an hGH graft were
depleted of CD4 T cells, regrafted with a further hGH graft,
and treated with agonist anti-CD40 antibody to provide a
costimulatory signal, or with control rat serum, at 0, 5, 10,
15, and 20 days after grafting. Rejection of second hGH grafts
occurred in 53% (8 out of 15) of mice receiving the CD40
stimulatory antibody FGK45 (Figure 2b), and in 0% (0 out
of 6) mice receiving rat IgG, demonstrating that CD40
stimulation could substitute for primed antigen-specific CD4
cells in promoting graft rejection by CD8 T cells from a
primed animal.
Primed, OVA-specific CD8 T cells can reject second-set
OVA-expressing skin grafts without the need for help
To examine further how help from CD4 T cells enables CD8
T-cell-mediated rejection of skin grafts in antigen-primed
recipients, we used an antigen, OVA, for which CD8 and
CD4 major histocompatibility complex (MHC) Class I- and
II-restricted epitopes are known, and for which mice with
T cells transgenic for T-cell receptors recognizing CD4- and
CD8-restricted OVA epitopes are available. We first grafted
skin from mice expressing a membrane-associated form of
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Figure 1. hGH graft-primed animals require CD4 T cells for optimal second
graft rejection. (a, b) Graft survival time is shown for (a) naive or
K14hGH.C57 graft-primed C57Bl/6 animals (n¼ 12) that received a
K14hGH.C57 or a C57Bl/6 graft, and for (b) K14hGH.C57 graft-primed
animals that received a K14hGH.C57 graft with or without simultaneous
depletion of CD4 T cells. Graft survival was compared using the log-rank
(Mantel–Cox) test. Multiple mice rejecting grafts on the same day are shown as
a single graph point on that day. (c, d) For control antibody-treated (c) and
GK1.5 anti-CD4-treated (d) animals, efficacy of CD4 cell depletion was
assessed by flow cytometry analysis of peripheral blood, using anti-CD4 and
anti-CD3mAb. Percentage of CD4 cells at 7 days is shown for each treatment.
Results are combined from two experiments.
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OVA from a keratin 5 promoter (K5-mOVA). K5-mOVA graft
recipients successfully rejected their grafts, with a median
survival time of 19 days. OVA graft-primed recipients were
then depleted of CD4 cells, and received a second K5-mOVA
graft on the opposite flank. CD4 T-cell-depleted and OVA
graft-primed recipients of a second K5-mOVA graft rejected
the second graft with a median survival time of 12 days,
significantly shorter than the time to primary graft rejection
(P¼0.01; Figure 3a) and no different than the rejection time
(12 days) for OVA graft-primed and otherwise unmanipulated
animals.
To confirm that there was no requirement for CD4 cells for
rejection of OVA grafts by OVA-specific T cells, we
examined the response to a graft expressing a minimal
cytotoxic T lymphocyte epitope of OVA (SIINFEKL) expressed
from a keratin 14 promoter (K14.SIIN), and hence unable
to invoke antigen-specific CD4 cells. K14SIIN skin grafts
were rejected by 12 of 15 unprimed recipients in a median of
21 days. Recipients that had rejected a first K14.SIIN graft
were depleted of CD4 cells, and regrafted. All 10 recipients
rejected a repeat graft in a median of 11 days (Po0.0001;
Figure 3b), similar to that for OVA grafts. To further
investigate whether MHC Class 1-restricted CD8 T cells
are sufficient for rejection of K5.mOVA grafts, 1106
Rag1/ OT-I cells, specific for the MHC-1-restricted
SIINFEKL peptide, were transferred to immune-deficient
Rag1/ recipients (n¼4), which were then grafted with
K5-mOVA grafts. All four grafts were rejected, with a median
survival time of 10 days (Figure 5a). Thus, CD8 T cells are
sufficient to reject skin grafts expressing either OVA or the
major MHC Class 1-restricted CD8 epitope of OVA in
keratinocytes.
CD4 T cells alone are not sufficient for graft rejection
To establish whether CD4 T cells alone could effect rejection
of a K5.mOVA graft, 2.5 107 OT-II spleen cells, specific
for a CD4-restricted epitope of OVA, were transferred into
Rag1/ recipients (n¼ 16), which 3 days later received a
K5.mOVA skin graft. FACS staining of peripheral blood on
the day of grafting confirmed successful transfer of CD4 T
cells (Figure 4). K5.mOVA grafts (13 out of 16) were generally
accepted by immunodeficient Rag 1/ animals, irrespec-
tive of whether they received OVA-specific CD4 OT-II
T cells (P¼0.37; Figure 4), in contrast to the findings for
OVA-specific CD8 T cells described above. Thus, OVA-
specific CD4 T cells are unable, in the absence of
OVA-specific CD8 cytotoxic T cells, to reject OVA-expressing
skin grafts.
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Figure 2. CD40 stimulation abrogates the requirement for CD4 cells to
enable rejection of hGH grafts from hGH-primed animals. (a) Graft survival
over time for K14hGH.C57 grafts (n¼ 15) and for C57Bl/6 grafts (n¼6)
placed on hGH graft-primed and CD4-depleted C57Bl/6 recipients treated
with agonist CD40 antibody FKG 45. (b) Graft survival over time for
K14hGH.C57 grafts placed on graft-primed and CD4-depleted C57Bl/6
recipients, treated either with agonist CD40 antibody (n¼15) or with control
antibody (n¼ 6). Graft survival differences were assessed for significance
using th log-rank (Mantel–Cox) test. Results are from three separate
experiments.
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Figure 3. Ovalbumin and SIINFEKL-expressing skin grafts do not require
CD4 cells for rejection. (a) Graft survival over time is shown for K5.mOVA
grafts placed on naive, or OVA graft-primed and CD4-depleted C57Bl/6-
recipient animals (n¼ 12). (b) Graft survival over time is shown for K14
SIINFEKL grafts placed on naive or SIINFEKL graft-primed and CD4-depleted
C57Bl/6-recipient animals (n¼12). Survival differences were assessed for
significance using the log-rank (Mantel–Cox) test.
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The number of transferred Rag-OT-I spleen cells determines the
rate of K5mOVA graft rejection
As CD4 T cells are necessary for rejection of skin expressing
hGH but not OVA from naive and antigen-primed animals,
and are insufficient to achieve rejection of skin grafts without
CD8 T cells, we investigated whether CD4 T cells might
accelerate CD8 T cell-mediated K5.mOVA skin graft rejec-
tion. OT-I OVA-specific CD8 cytotoxic T cells (106) were
transferred with or without OT-II OVA-specific CD4 helper
T cells (106) to immunodeficient recipient animals 3 days
before grafting with K5m.OVA skin. Grafts were rejected in a
median of 10 days, irrespective of whether OT-II cells were
transferred (Figure 5b). To establish whether CD4 cells might
contribute to rejection when antigen-specific CD8 T cells
were present in limiting numbers, a graded number of
Rag-OT-1 OVA-specific CD8 spleen cells were combined
with sufficient irrelevant TCR transgenic T cells to equalize
the total number of transferred T cells and minimize T-cell
activation through homeostatic proliferation, which would
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Figure 4. Transfer of CD4 T cells alone does not significantly increase graft
rejection. (a) Survival over time of OVA grafts placed on immunodeficient
Rag1/ recipients (n¼16) reconstituted with 2.5 107 OVA-specific helper
T cells from OT-II transgenic spleen or on control Rag 1/ animals receiving
no cells (n¼ 8). (b, c) Effective transfer of OVA-specific helper T cells from
OTII mice was confirmed by staining of peripheral blood from mice receiving
OT-II cells (b) and control mice (c) with anti-CD3 and anti-Va2 antibodies
specific for OT-II cells. Results are from two separate experiments.
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Figure 5. The rate of K5mOVA graft rejection is dependent on CD8
precursor frequency and CD4 T cells. (a) Immunodeficient Rag1/ recipients
of K5.mOVA grafts received increasing numbers of Rag/ OTI OVA-specific
CD8 T cells from spleen as shown, together with sufficient irrelevant TCR
transgenic T cells to equalize the number of transferred cells, and graft
survival was observed (nX4 per group). (b) Rag-OT-I OVA-specific CD8
T cells from spleen (106) were administered with (n¼ 4) or without (n¼ 4)
OVA-specific T-helper (OT-II) spleen cells (106) to immunodeficient Rag1/
recipients. After 3 days, K5mOVA skin grafts were placed and followed up to
rejection. (c) Rag/ 2C immunodeficient mice received 102 OVA-specific
CD8 OT-1 cells, or 102 OT-1 cells and 106 OVA-specific CD4 OT-2 cells.
K5.mOVA skin grafts were placed and followed up to rejection. Graft survival
over time is shown. Survival differences were assessed for significance using
the log-rank (Mantel–Cox) test. Results are from two separate experiments.
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otherwise occur in the T cell-deficient Rag 1/ recipient.
Rejection of OVA grafts from these immune-reconstituted
animals was fastest in animals recipient of larger numbers
of transferred OT-1 cells (P¼ 0.0082; Figure 5a). To
determine whether there was a role of OVA-specific helper
CD4 T cells in graft rejection when OVA-specific CD8 cell
numbers were limited, 102 OVA-specific CD8 T cells were
transferred to 2C TCR transgenic recipients, which have
normal numbers of T cells without any OVA-specific T-cell
repertoire. OVA-specific OT-1 CD8 T cells of ‘‘naive’’
phenotype, as shown (Figure 6a and b), were transferred
with or without 106 OVA-specific OT-II CD4 T cells
(Figure 5c). K5.mOVA skin grafts were rejected from
recipients of OVA-specific CD8 spleen cells alone, with a
median survival time of 40 days. When both OVA-specific
CD8 and OVA-specific CD4 T cells were transferred, median
graft survival time was significantly shorter at 16 days
(P¼0.022). Thus, in animals with physiological precursor
frequencies of antigen-specific CD8 T cells of 100–1000
(Lammermann and Sixt, 2008), antigen-specific CD4 T cells
enhance skin graft rejection.
CD4 T-cell help for memory CD8 T cells
OVA-specific CD4 T cells might enhance OVA graft rejection
by OVA-specific CD8 cells in the previously described
experiments by assisting the priming of naive OVA-specific
CD8 T cells. To investigate whether memory CD8 T-cell
function could also be enhanced by CD4 T cells, we created
CD8 memory T cells specific for OVA in vitro by a protocol
shown to produce cells predominantly of a central memory
phenotype (CD44CD62Lhi), and 98% of cells demonstrated
this phenotype (Figure 6). Memory phenotype OVA-specific
CD8 OT-1 cells (100/animal) were then transferred to
Rag1/ C57 mice bearing a K5.mOVA skin graft, with or
without 106 CD4-enriched OVA-specific cells from OT-II
mice (Figure 6c). Grafts were rejected by mice receiving
OT-1 CD8 central memory T cells alone, with a median graft
survival time of 24 days. Mice receiving both OT-I CD8
central memory T cells and OT-II OVA-specific CD4 cells
(n¼7) rejected grafts more quickly, with a median survival
time of 12 days (P¼0.008; Figure 6d). Thus, OVA-specific
CD4 T cells enhanced graft rejection by activated OVA-
specific CD8 T cells, confirming that antigen-specific CD4
T cells can assist primed antigen effector and memory CD8
T-cell function in eliminating skin grafts expressing antigen in
keratinocytes.
DISCUSSION
The data presented here show that antigen-specific CD4
T cells can enhance the function of antigen-primed effector
and memory CD8 T cells, and hence enable, or increase the
rapidity of, rejection of keratinocytes expressing non- or neo-
self-antigen. Further, the function of CD4 T cells can be
substituted by CD40 stimulation, suggesting that the likely
mechanism of CD4-mediated enhancement is activation of
APCs cross-presenting antigen to CD8 T cells. These findings
provide in vivo evidence to complement previous in vitro
generated data (Blachere et al., 2006) that CD8 effector
function is enhanced by antigen-specific CD4 T cells, and
extend this finding specifically to keratinocyte elimination.
Our previous observations for hGH antigen on an F1 (H-2
bH-2q) genetic background demonstrated that CD8 T cells
were necessary for elimination of keratinocytes, that CD4
T cells assisted the process, and that antibody, although
induced, was not sufficient to enable rejection (Zhong et al.,
2004, 2008). Extension of this observation from H-2q to H-2b
mice eliminates the possibility that the previous findings
represented a genetically determined limitation of CD8 T-cell
function in F1 (H-2qH-2b) animals, as H-2q mice did not
present hGH as a neo-self-antigen for rejection.
As the mechanism by which epithelial cells expressing
antigen are eliminated by CD8 T cells is uncertain, it was
important to establish that CD4 T cells themselves were not
effecting graft rejection in cases in which antigen was
expressed in keratinocytes, as it is well recognized that
allograft rejection can occur by meansk of an CD4-depen-
dent and MHC class II-restricted mechanism (Rosenberg
et al., 1989). Large numbers of antigen-specific CD4 T cells
were unable to induce graft rejection in our model, indicating
that direct cellular cytotoxicity by CD4 T cells is unlikely to
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Figure 6. CD4 T cells provide help to activated CD8 T cells. (a, b) OT-I CD8
Ova-specific T cells, either activated in vitro (left panels) or not so activated
(‘‘naive’’; right panels), were assessed for CD8, CD44 (a), or CD62L (b)
expression by flow cytometry. (c) OT-II spleen cells were enriched for OVA-
specific T-helper cells using anti-CD4 magnetic beads and enrichment
assessed with anti-CD4 and -CD3 antibodies by flow cytometry. (d) Mice
received 102 activated OVA-specific CD8 OT-I cells (n¼7) or 102 activated
OT-I and 106 CD4-enriched OVA-specific helper OT-II cells (n¼ 7).
K5.mOVA skin grafts were placed and followed up to rejection. Graft survival
over time is shown. Survival differences were assessed for significance using
log-rank (Mantel–Cox) test.
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account for the help provided in the enhancement of skin
graft rejection in this system.
CD4 T cells assist priming of naive CD8 T cells (Mintern
et al., 2002c), activating DCs to express costimulatory
molecules and providing key cytokines for CD8 T-cell
expansion, including IL-2. High precursor frequencies of
antigen-specific CD8 T cells can overcome the need for
CD4 T cells, as evidenced by OVA-specific cytotoxicity ex
vivo of OT-I T cells generated in MHC II-deficient hosts
(Mintern et al., 2002a, b; Wang et al., 2007; Salek-Ardakani
et al., 2008). The precursor frequency of antigen-specific
CD8 T cells determines the fate of skin grafts, and previous
experiments have established that for priming of responses
to OVA, expressed constitutively in all cells including APC,
higher precursor frequency abrogates the need for CD28-
and CD154-mediated costimulation to expand the precursor
pool (Ford et al., 2007). However, although priming can
occur in the absence of help from antigen-specific CD4
T cells, particularly if CD8 cells generate their own IL-2,
availability of antigen-specific CD4 cells at priming seems
to be critical for generation of central memory CD8 T cells
(Fernando et al., 2002; Castellino and Germain, 2007;
Fuse et al., 2009).
More recently, CD4 T cells have also been shown in vitro
to have a role in the reactivation of memory cells through a
mechanism in which IL-2 has a part, although it cannot
entirely substitute for CD 4 cells (Blachere et al., 2006). In our
experiments, OT-I OVA-specific CD8 T cells were sufficient
to reject a K5mOVA graft from a Rag/ mouse, and the rate
of rejection was related to the number of transferred Rag OT-I
cells. Thus, at least for OVA, the requirement for CD4 T cells
is not absolute, and likely assists in amplification of effector
numbers. IL-2-dependent proliferation of CD8 memory cells
(Mintern et al., 2002c) is important in increasing cell
numbers, and production of IL-2 by OT-1 cells in response
to antigen is well described. Proliferation of CD8 cells can
occur locally in target tissue (Wakim et al., 2008b; Kim et al.,
2009) and CD4 T cells may help activate local dendritic cells
(Wakim et al., 2008a), as these have also been shown to have
a role in enabling memory T-cell function, or upregulate
MHC Class 1 presentation on KC, as these cells can also
promote proliferation of antigen-specific T cells in vivo, even
in the absence of professional APC (Kim et al., 2009). Our
data, however, show that, as OT-1 cells are sufficient to
enable rejection of well-healed skin grafts from CD4-
deficient animals, local dendritic cell activation and CD4
T-cell induction are not mandatory for CD8 effector function
for a nonself-antigen, as they seem to be for a neo-self-
antigen, but rather assist in amplifying the CD8 effector
response. We have previously established in a graft model, in
which the target antigen is the E7 protein of human
papillomavirus 16, that the inflammation associated with
grafting promotes local CD8 effector T-cell function in an
antigen-primed host, as well-healed grafts are relatively
resistant to CD8 T-cell function (Matsumoto et al., 2004). In
the hGH graft rejection model, in which the antigen is a neo-
self-antigen, and partial tolerance would be expected (Zhong
et al., 2004), inflammation and CD4 cells were required for
CD8 effector function, and we now show that CD40
costimulation was able to substitute for CD4 T cells, as has
been shown in other systems (Hernandez et al., 2008). Our
system differs from previous data in demonstrating the
enhancement of a secondary immune response by CD40
costimulation. This suggests a role for CD40 signaling in
antigen presentation to memory CD8 T cells. Together, these
data demonstrate that the likely in vivo mechanism of
enhancement of skin graft rejection by CD4 cells and local
inflammation involves an effective cross-presentation of
antigen by CD4-activated APC in skin to enable amplification
of CD8 T-effector cells. Alternatively, although less likely,
direct CD40 stimulation of CD8 T cells may enhance
cytotoxic T lymphocyte function and could account for
rejection mediated by CD40 stimulation in this system
(Bourgeois et al., 2002). A further mechanism by which
inflammation may promote graft rejection is through chemo-
kine-mediated attraction of T cells (Castellino and Germain,
2007), both antigen-specific and nonspecific (Wakim et al.,
2008b), to the site of grafting, enabling selective proliferation
of antigen-specific effector cells.
Elucidation of the cellular requirements for an effective
immune response to antigen that is cross-presented at the
epithelium has significant clinical relevance. Failure to clear
chronic human papillomavirus infection leads in some cases
to cervical cancer, and many epithelial cancers express
tumor-specific antigens. Both nonself-antigen and neo-self-
antigen presentations in these clinical scenarios are chronic,
invoking regulatory rather than effector CD4 responses, our
data demonstrate that absence of antigen-specific helper CD4
T cells may significantly impair the effectiveness of effector
or memory CD8 T-cell responses to neo-self-antigen in
keratinocytes, whether the immune response is induced by
specific immunotherapy or in response to antigen cross-
presented from an epithelial tumor. They therefore support
the need for induction of appropriate CD4 T-cell responses as
part of any immunotherapeutic intervention targeted at the
epithelium.
MATERIALS AND METHODS
Mice
All experimental protocols were approved by the animal ethics
committee of the University of Queensland. Mice were maintained
under conventional conditions in specific pathogen-free holding
rooms in the Princess Alexandra Hospital Biological Resources
Facility, University of Queensland.
Transgenic mice used in these studies are detailed in Table 1.
OT-II and K5m.OVA mice were obtained from Dr W.R. Heath,
Walter and Eliza Hall Institute, Parkville, Australia. OT-I and
Rag1/ mice were purchased from the Animal Resource Centre,
Perth Australia. 2C mice were obtained from Dr B. Fazekas,
Centenary Institute, Sydney. K14hGH.H-2b mice were produced
by backcrossing male K14hGH.H-2q mice obtained from Dr Jie
Zhong, Diamantina Institute with C57Bl/6 mice for 10 generations.
To assess whether backcrossing had successfully generated a C57Bl/6
background, offspring not expressing hGH were used as skin graft
donors. Ear skin grafts applied to the flanks of C57Bl/6 recipients
were uniformly accepted, indicating histocompatibility.
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Screening of transgenic mice
To screen for the K14.hGH transgene, serum hGH was assayed using
the Bioclone Elegance Growth Hormone ELISA Kit (Bioclone
Australia Pty Ltd, Sydney, NSW, Australia) according to the
manufacturer’s instructions. To screen for the K5.mOVA transgene,
DNA from tail tips was detected by PCR with forward primer
50-CTGTGCAGATGATGTAC-30 and reverse primer 50-TGGTTGCG
ATGTGCTTG-30.
Skin grafting
Whole-thickness ear skin grafting was performed as previously
described (Frazer et al., 1998). Grafts were examined every second
day and were classified as rejected if there was 480% loss of
epithelium, and as accepted if there was no rejection by day 50.
Rejection or acceptance of transgenic skin was confirmed geneti-
cally and histologically in a random sample of mice. In cases in
which repeat grafting was undertaken, it was performed on the
opposite flank.
CD4 cell depletion
CD4 cells were depleted by intraperitoneal injection with anti-CD4
mAb (GK1.5) at 1mg per mouse at 3 days before grafting. An equal
amount of rat IgG was used as a control. Efficacy of depletion was
evaluated by FACS staining of 100–200 ml peripheral blood. Briefly,
peripheral blood mononuclear cells were prepared and washed with
FACS buffer (1% FCS in phosphate-buffered saline (PBS)). Cells were
stained with FITC-conjugated anti-CD4 (RM4-4, BD Biosciences,
San Jose, CA; RM4-4 does not cross-compete with GK1.5) and
phycoerythrin-conjugated anti-CD3 (BD Biosciences) mAbs and
visualized with flow cytometry.
mAb production
Anti-mouse CD40 agonist Rat IgG2a antibody was isolated from
FGK45 hybridoma cells used with permission from Professor
Antionius Rolink (Basel Institute, Switzerland). Briefly, FGK45
cells were cultured, and the protein produced was isolated with a
protein G column and quantified by the NanoDrop 1000 spectro-
photometer (Thermo Scientific, Wilmington, DE). Rat IgG was
prepared by separating an Ig-enriched fraction of rat serum by
ammonium sulfate precipitation. The product was dialyzed against
PBS, filtered (0.2mm filter), and the protein concentration was
measured by the BCA Protein Assay kit (Pierce, Thermo Scientific,
Rockford, IL). Antibody was administered according to a published
schedule (Fischbein et al., 2000) that was shown to be effective in our
laboratory.
Preparation and transfer of spleen cells
A single cell suspension of spleen cells in DMEM (Invitrogen,
Carlsbad, CA) was prepared. Red cells were lysed by addition of 2ml
ACK lysing buffer (Invitrogen), and cells were washed in sterile PBS.
Table 1. Designation of transgenic animals
Designation
Genetic
background Transgene genotype Phenotype Function Reference
OT-II H-2b TCR gene-specific for
OVA323339 peptide
bound on IAb
Most T cells are CD4 helper T cells
specific for OVA presented in the
context of MHC Class II
Source of CD4 helper T cells
specific for OVA presented by
antigen-presenting cells
Barnden et al.
(1998)
OT-1 H-2b Rag/ TCR gene-specific for
OVA peptide SIINFEKL
bound on H-2Kb No
recombinase activation
genes
All T cells are CD8 cytotoxic T cells
specific for OVA presented in the
context of MHC Class I
Source of CD8 cytotoxic T cells
specific for OVA presented by
somatic cells
Hogquist et al.
(1994)
K5.mOVA H-2b OVA expressed from
a keratin 5 promoter
Squamous epithelial keratinocytes
express OVA peptides for direct
and cross-presentation
Source of skin-presenting
OVA in somatic cells that can
also be cross-presented by
antigen-presenting cells
Azukizawa et al.
(2003)
K14.SIIN H-2b OVA MHC Class I restricted
peptide SIINFEKL expressed
from a keratin 14 promoter
Squamous epithelial keratinocytes
express OVA peptide for direct
presentation to CD8 T cells. Also
express low levels of human growth
hormone due to leaky transgene
construct
Source of skin-presenting OVA
peptide in somatic cells that
cannot be cross-presented by
antigen-presenting cells
McGargill et al.
(2002)
2C H-2b TCR gene-specific
for H-2 Ld
No recombinase
activation genes
All T cells are CD8 cytotoxic T cells
specific for an irrelevant foreign
MHC molecule
A mouse with normal numbers
of T cells, none of which can
recognize OVA
H-2Ld Sha et al.
(1990)
K14hGH H-2q or H-2b Human growth hormone
expressed from a keratin
14 promoter
Squamous epithelial keratinocytes
express human growth hormone
peptides for direct and
cross-presentation
Source of skin-presenting human
growth hormone in somatic cells
that can also be cross-presented
by antigen-presenting cells
Zhong et al.
(2004)
Abbreviations: MHC, major histocompatibility complex; OVA, ovalbumin.
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Cell viability was determined by Trypan blue (Invitrogen) dye
exclusion.
In vitro activation of OT-1 T cells
OT-I T cells were in vitro activated as described by Kenna et al.
(2008). Briefly, OT-I lymph node cells were harvested and cultured
in complete RPMI (RPMI 1640 supplemented with 1mM sodium
pyruvate, 0.1mM nonessential amino acids, 50 mM 2-ME) with 1%
normal mouse serum, 0.1mgml1 OVA257264, and 10 ngml
1 IL-2.
After 3 days, cells were harvested and washed (3 ) with RPMI 1640
and recultured in six-well plates at 2 106/ml in the absence of
antigen but with 10 ngml1 IL-15 for an additional 5 days. Cells
were harvested, washed, and resuspended in sterile PBS before
transfer to recipients.
Purification of OT-II cells by positive selection
A single cell suspension of OT-II spleen cells was resuspended at
90 ml 4% fetal bovine serum in sterile PBS per 107 cells and
incubated with MACS anti-CD4 beads (Miltenyi Biotech, Bergisch
Gladbach, Germany) (10 ml beads per 107 total cells) for 15minutes
at 4 1C. Magnetic separation was performed with the autoMACS
Separator (Miltenyi Biotec, 51429 Bergisch Gladbach, Germany)
using the Possel positive selection program as per the manufacturer’s
instructions (Miltenyi Biotec). Purity was assessed by FACS staining
with anti-CD4 (FITC conjugated, BD Pharmingen, North Ryde,
NSW, Australia), and anti-CD3 (PE conjugated, eBioscience, Jomar
Bioscience, Kensington, SA, Australia). Cells were washed twice in
sterile PBS before transfer.
Statistics
Statistical comparisons were determined by Mantel–Cox analysis of
Kaplan–Meier survival curves. Differences with Po0.05 were
considered significant.
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